Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length

Journal of Neuroscience

Volumn 22, Issue 9, 2002, Pages 3473-3483

  De Almeida, Luis Pereira ^a,b   Ross, Christopher A ^c   Zala, Diana ^a,d   Aebischer, Patrick ^a,d   Déglon, Nicole ^a,d  

^a University of Lausanne Medical Center   (Switzerland)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EPFL   (Switzerland)

Author keywords

Gene delivery; Genetic model; Huntingtin; Huntington's disease; Lentiviral vector; Rat

Indexed keywords

AMINO ACID; CYCLIC AMP; DOPAMINE; HUNTINGTIN; LENTIVIRUS VECTOR; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE KINASE 1; PHOSPHOPROTEIN; POLYGLUTAMINE; UNCLASSIFIED DRUG; HD PROTEIN, HUMAN; HDH PROTEIN, RAT; NERVE PROTEIN; NUCLEAR PROTEIN; PEPTIDE; PHOSPHOPROTEIN DARPP 32;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; CYTOMEGALOVIRUS; DOPAMINE RELEASE; FEMALE; GENE TRANSFER; GENETIC CODE; GENETIC MODEL; HUNTINGTON CHOREA; INJECTION SITE; MODULATION; MUTATOR GENE; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RAT; VIRAL GENE DELIVERY SYSTEM; WILD TYPE; ANIMAL; BIOSYNTHESIS; CELL INCLUSION; CELL LINE; CELL NUCLEUS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; LENTIVIRINAE; METABOLISM; MICROINJECTION; MUTATION; PATHOLOGY; TISSUE DISTRIBUTION; TRINUCLEOTIDE REPEAT; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL NUCLEUS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; HUNTINGTON DISEASE; INCLUSION BODIES; LENTIVIRUS; MICROINJECTIONS; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PEPTIDES; PHOSPHOPROTEINS; PROMOTER REGIONS (GENETICS); RATS; RATS, WISTAR; TISSUE DISTRIBUTION; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 0036580677     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-09-03473.2002     Document Type: Article

References (70)

1. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, Graham RK, Hayden MR (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4:398-403.
2. Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR, Rosser AE, Wood NW, Brooks DJ (1999) Huntington's disease progression. PET and clinical observations. Brain 122:2353-2363.
3. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yebenez JG, Boesiger P, Weindl A, Maguire RP (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119:2085-2095.
4. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ (1994) Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 44:823-828.
5. Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, Barta PE, Pearlson GD, Ross CA (2000) Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 15:552-560.
6. Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA (1998) Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 4:387-397.
7. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, Nairn AC, Messer A, Greengard P (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci USA 97:6809-6814.
8. Blömer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH (1997) Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 71:6641-6649.
9. Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, Kaminsky Z, Masone J, Khan FA, Delanoy M, Borchelt DR, Dawson VL, Dawson TM, Ross CA (1998) Truncated N-terminal fragments of Huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 7:783-790.
10. Craufurd D, Dodge A (1993) Mutation size and age at onset in Huntington's disease. J Med Genet 30:1008-1011.
11. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-548.
12. de Almeida PL, Zala D, Aebischer P, Déglon N (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 8:433-446.
13. Déglon N, Tseng JL, Bensadoun JC, Zurn AD, Arsenijevic Y, Pereira de Almeida L, Zufferey R, Trono D, Aebischer P (2000) Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther 11:179-190.
14. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.
15. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, Ross C, Franz M, Abbott M, Gray J, Conneally P, Young A, Penney J, Hollingsworth Z, Shoulson I, Lazzarini A, Falek A, Koroshetz W, Sax D, et al. (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4:387-392.
16. Ellison DW, Kowall NW, Martin JB (1987) Subset of neurons characterized by the presence of NADPH-diaphorase in human substantia innominata. J Comp Neurol 260:233-245.
17. Evert BO, Wüllner U, Schulz JB, Weller M, Groscurth P, Trottier Y, Brice A, Klockgether T (1999) High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Hum Mol Genet 8:1169-1176.
18. Ferrante RJ, Beal MF, Kowall NW, Richardson EP, Martin JB (1987) Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 411:162-166.
19. Furtado S, Suchowersky O, Rewcasle NB, Graham L, Klimek ML, Garber A (1996) Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 39:132-136.
20. Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA, Srinidhi J, Gusella JF, Bird ED, Vonsattel JP, Myers RH (2001) Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol 49:29-34.
21. Grafton ST, Mazziotta JC, Pahl JJ, St. George-Hyslop P, Haines JL, Gusella J, Hoffman JM, Baxter LR, Phelps ME (1990) A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol 28:614-621.
22. Greengard P, Allen PB, Naim AC (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23:435-447.
23. Hodgson JG, Agopyan N, Gutekunst C-A, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li X-J, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181-192.
24. Holmberg M, Duyckaerts C, Durr A, Cancel G, Gourfinkel-An I, Damier P, Faucheux B, Trottier Y, Hirsch EC, Agid Y, Brice A (1998) Spino-cerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet 7:913-918.
25. Hottinger AF, Azzouz M, Déglon N, Aebischer P, Zurn AD (2000) Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci 20:5587-5593.
26. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell 72:971-983.
27. Hurlbert MS, Zhou W, Wasmeier C, Kaddis FG, Hutton JC, Freed CR (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48:649-651.
28. Kafri T, van Praag H, Gage FH, Verma IM (2000) Lentiviral vectors: regulated gene expression. Mol Ther 1:516-521.
29. Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW, Steinman L (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc Natl Acad Sci USA 96:7388-7393.
30. Kim M, Lee H-S, LaForet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M (1999) Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 19:963-973.
31. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Déglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773.
32. Kosinski CM, Cha J-H, Young AB, Mangiarini L, Bates G, Schiefer J, Schwarz M (1999) Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. NeuroReport 10:3891-3896.
33. Koyano S, Uchihara T, Fujigasaki H, Nakamura A, Yagishita S, Iwabuchi K (1999) Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study. Neurosci Lett 273:117-120.
34. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ (1999) Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 46:842-849.
35. Li H, Li S-H, Cheng AL, Mangiarini L, Bates GP, Li X-J (1999) Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet 8:1227-1236.
36. Li H, Li S-H, Johnston H, Shelbourne PF, Li X-J (2000) Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25:385-389.
37. Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, Doyu M, Hashizume Y, Fischbeck KH, Sobue G (1998) Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 44:249-254.
38. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10:137-144.
39. Lunkes A, Mandel J-L (1998) A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 7:1355-1361.
40. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha JH, Olson JM (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9:1259-1271.
41. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.
42. Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja R, Kazemi-Esfarjani P, Devon R, Kim SU, Bredesen DE, Tufaro F, Hayden MR (1998) Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 18:150-154.
43. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, Hoffman JM, Kuhl DE, Lanto AB, Wapenski JA, Markham CH (1987) Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 316:357-362.
44. Menalled L, Zanjani H, MacKenzie L, Koppel A, Carpenter E, Zeitlin S, Chesselet MF (2000) Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol 162:328-342.
45. Naldini L (1998) Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 9:457-463.
46. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996) In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 272:263-267.
47. Ory DS, Neugeboren BA, Mulligan RC (1996) A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 93:11400-11406.
48. Ouimet CC, Langley-Gullion KC, Greengard P (1998) Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res 808:8-12.
49. Paulson HL (2000) Toward an understanding of polyglutamine neurodegeneration. Brain Pathol 10:293-299.
50. Persichetti F, Ambrose CM, Ge P, McNeil SM, Srinidhi J, Anderson MA, Jenkins B, Barnes GT, Duyao MP, Kanaley L, Wexler NS, Myers RH, Bird ED, Vonsattel J-P, MacDonald ME, Gusella JF (1995) Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. Mol Med 1:374-383.
51. Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO, Miller G, Tagle DA (1998) Behavioral abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20:198-202.
52. Reddy PH, Charles V, Williams M, Miller G, Whetsell Jr WO, Tagle DA (1999a) Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos Trans R Soc Lond B Biol Sci 354:1035-1045.
53. Reddy PH, Williams M, Tagle DA (1999b) Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci 22:248-255.
54. Reynolds DS, Carter RJ, Morton AJ (1998) Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J Neurosci 18:10116-10127.
55. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, Cattaneo E (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705-3713.
56. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66.
57. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397-407.
58. Schilling G, Jinnah HA, Gonzales V, Coonfield ML, Kim Y, Wood JD, Price DL, Li XJ, Jenkins N, Copeland N, Moran T, Ross CA, Borchelt DR (2001) Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. Neurobiol Dis 8:405-418.
59. Schmued LC, Hopkins KJ (2000) Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 874:123-130.
60. Schmued LC, Albertson C, Slikker W (1997) Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 751:37-46.
61. Senut M-C, Suhr ST, Kaspar B, Gage FH (2000) Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. J Neurosci 20:219-229.
62. Shelbourne PF, Killeen N, Hevner RF, Johnston HM, Tecott L, Lewandoski M, Ennis M, Ramirez L, Li Z, Iannicola C, Littman DR, Myers RM (1999) A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioral abnormalities in mice. Hum Mol Genet 8:763-774.
63. Sisodia SS (1998) Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? Cell 95:1-4.
64. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, MacDonald ME, Gusella JF, Harper PS, Shaw DJ (1993) Relantionship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 4:393-397.
65. van Dellen A, Welch J, Dixon RM, Cordery P, York D, Styles P, Blakemore C, Hannan AJ (2000) N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. NeuroReport 11:3751-3757.
66. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369-384.
67. Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A, Duyao MP, Vrbanac V, Weaver M, Gusella JF, Joyner AL, MacDonald ME (1999) Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet 8:115-122.
68. White JK, Auerbach W, Duyao MP, Vonsattel J-P, Gusella JF, Joyner AL, MacDonald ME (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17:404-410.
69. Wilkinson FL, thi Man N, Manilal SB, Thomas P, Neal JW, Harper PS, Jones AL, Morris GE (1999) Localization of rabbit huntingtin using a new panel of monoclonal antibodies. Brain Res Mol Brain Res 69:10-20.
70. Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101:57-66.